Loading…
Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide–Protease Fusions
We have developed a new concept for designing peptidic protein modulators, by recombinantly fusing the peptidic modulator, with randomized residues, directly to the target protein via a linker and screening for internal modulation of the activity of the protein. We tested the feasibility of the conc...
Saved in:
Published in: | Journal of molecular biology 2015-09, Vol.427 (19), p.3110-3122 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c423t-2d9c154cd51c2eba2b0a2052500da1ecc53b24d429daa1931e0dcea7312a0c6a3 |
---|---|
cites | cdi_FETCH-LOGICAL-c423t-2d9c154cd51c2eba2b0a2052500da1ecc53b24d429daa1931e0dcea7312a0c6a3 |
container_end_page | 3122 |
container_issue | 19 |
container_start_page | 3110 |
container_title | Journal of molecular biology |
container_volume | 427 |
creator | Sørensen, Hans Peter Xu, Peng Jiang, Longguang Kromann-Hansen, Tobias Jensen, Knud J. Huang, Mingdong Andreasen, Peter A. |
description | We have developed a new concept for designing peptidic protein modulators, by recombinantly fusing the peptidic modulator, with randomized residues, directly to the target protein via a linker and screening for internal modulation of the activity of the protein. We tested the feasibility of the concept by fusing a 10-residue-long, disulfide-bond-constrained inhibitory peptide, randomized in selected positions, to the catalytic domain of the serine protease murine urokinase-type plasminogen activator. High-affinity inhibitory peptide variants were identified as those that conferred to the fusion protease the lowest activity for substrate hydrolysis. The usefulness of the strategy was demonstrated by the selection of peptidic inhibitors of murine urokinase-type plasminogen activator with a low nanomolar affinity. The high affinity could not have been predicted by rational considerations, as the high affinity was associated with a loss of polar interactions and an increased binding entropy.
[Display omitted]
•The back-flip strategy, as demonstrated here with a peptidic protease inhibitor, provides a practical approach to engineering peptidic protein modulators in general and to mapping peptide–protein interaction surfaces.•The usefulness of the back-flip strategy is demonstrated by a rationally unpredictable improvement of a peptidic protease inhibitor following the loss of a peptide–protein polar interaction and an entropy penalty.•The high affinity of the new peptidic inhibitors to their target enzyme appears to be caused by their flexibility, enabling them to adapt to variable enzyme surfaces. |
doi_str_mv | 10.1016/j.jmb.2015.08.005 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1715659932</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022283615004507</els_id><sourcerecordid>1715659932</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-2d9c154cd51c2eba2b0a2052500da1ecc53b24d429daa1931e0dcea7312a0c6a3</originalsourceid><addsrcrecordid>eNp9kcFu3CAURVHVKplO8wHdVCy7sQvYOLa6SqJME2mkRkq6RhieM29qgwueVLPrPyRf2C8p1qRZZoUQhwPvXkI-cpZzxqsv23w7tLlgXOaszhmTb8iCs7rJ6qqo35IFY0Jkoi6qY_I-xi1LRFHWR-RYVKLmp5wvyNMt9GAm9I76jl7h_SY76zp0OO3pDYwTWjT0FgI6oDfBT6Aj0Gu3wRYnHyL9jdMm7U2YDyw9R2fR3dNLNwU_7mkX_EA1PdfmZ7bqcaRrbIMO-_mxgx7-_nl8Ea92Mf0kfiDvOt1HOHlel-TH6vLu4ipbf_92fXG2zkwpiikTtjFclsZKbgS0WrRMCyaFZMxqDsbIohWlLUVjteZNwYFZA_q04EIzU-liST4fvGPwv3YQJzVgNND32oHfRZUikpVsmkIklB9QE3yMATo1BhzSJIozNZehtiqVoeYyFKvVHPWSfHrW79oB7MuN_-kn4OsBgDTkA0JQ0SA4AxZDKkVZj6_o_wFq1Z1X</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1715659932</pqid></control><display><type>article</type><title>Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide–Protease Fusions</title><source>ScienceDirect Freedom Collection</source><creator>Sørensen, Hans Peter ; Xu, Peng ; Jiang, Longguang ; Kromann-Hansen, Tobias ; Jensen, Knud J. ; Huang, Mingdong ; Andreasen, Peter A.</creator><creatorcontrib>Sørensen, Hans Peter ; Xu, Peng ; Jiang, Longguang ; Kromann-Hansen, Tobias ; Jensen, Knud J. ; Huang, Mingdong ; Andreasen, Peter A.</creatorcontrib><description>We have developed a new concept for designing peptidic protein modulators, by recombinantly fusing the peptidic modulator, with randomized residues, directly to the target protein via a linker and screening for internal modulation of the activity of the protein. We tested the feasibility of the concept by fusing a 10-residue-long, disulfide-bond-constrained inhibitory peptide, randomized in selected positions, to the catalytic domain of the serine protease murine urokinase-type plasminogen activator. High-affinity inhibitory peptide variants were identified as those that conferred to the fusion protease the lowest activity for substrate hydrolysis. The usefulness of the strategy was demonstrated by the selection of peptidic inhibitors of murine urokinase-type plasminogen activator with a low nanomolar affinity. The high affinity could not have been predicted by rational considerations, as the high affinity was associated with a loss of polar interactions and an increased binding entropy.
[Display omitted]
•The back-flip strategy, as demonstrated here with a peptidic protease inhibitor, provides a practical approach to engineering peptidic protein modulators in general and to mapping peptide–protein interaction surfaces.•The usefulness of the back-flip strategy is demonstrated by a rationally unpredictable improvement of a peptidic protease inhibitor following the loss of a peptide–protein polar interaction and an entropy penalty.•The high affinity of the new peptidic inhibitors to their target enzyme appears to be caused by their flexibility, enabling them to adapt to variable enzyme surfaces.</description><identifier>ISSN: 0022-2836</identifier><identifier>EISSN: 1089-8638</identifier><identifier>DOI: 10.1016/j.jmb.2015.08.005</identifier><identifier>PMID: 26281711</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Amino Acid Sequence ; Animals ; Cell Line ; conformation ; Crystallography, X-Ray ; Drug Discovery ; Entropy ; fusion protein ; glycine ; Humans ; Mice ; Molecular Sequence Data ; mupain-1 ; Peptide Library ; Peptides, Cyclic - chemistry ; Peptides, Cyclic - metabolism ; Peptides, Cyclic - pharmacology ; phage display ; Protein Conformation ; Recombinant Fusion Proteins - chemistry ; Recombinant Fusion Proteins - metabolism ; Serine Endopeptidases - chemistry ; Serine Endopeptidases - metabolism ; Serine Proteinase Inhibitors - chemistry ; Serine Proteinase Inhibitors - metabolism ; Serine Proteinase Inhibitors - pharmacology ; Urokinase-Type Plasminogen Activator - antagonists & inhibitors ; Urokinase-Type Plasminogen Activator - chemistry ; Urokinase-Type Plasminogen Activator - metabolism</subject><ispartof>Journal of molecular biology, 2015-09, Vol.427 (19), p.3110-3122</ispartof><rights>2015 Elsevier Ltd</rights><rights>Copyright © 2015 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-2d9c154cd51c2eba2b0a2052500da1ecc53b24d429daa1931e0dcea7312a0c6a3</citedby><cites>FETCH-LOGICAL-c423t-2d9c154cd51c2eba2b0a2052500da1ecc53b24d429daa1931e0dcea7312a0c6a3</cites><orcidid>0000-0003-0085-9141</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26281711$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sørensen, Hans Peter</creatorcontrib><creatorcontrib>Xu, Peng</creatorcontrib><creatorcontrib>Jiang, Longguang</creatorcontrib><creatorcontrib>Kromann-Hansen, Tobias</creatorcontrib><creatorcontrib>Jensen, Knud J.</creatorcontrib><creatorcontrib>Huang, Mingdong</creatorcontrib><creatorcontrib>Andreasen, Peter A.</creatorcontrib><title>Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide–Protease Fusions</title><title>Journal of molecular biology</title><addtitle>J Mol Biol</addtitle><description>We have developed a new concept for designing peptidic protein modulators, by recombinantly fusing the peptidic modulator, with randomized residues, directly to the target protein via a linker and screening for internal modulation of the activity of the protein. We tested the feasibility of the concept by fusing a 10-residue-long, disulfide-bond-constrained inhibitory peptide, randomized in selected positions, to the catalytic domain of the serine protease murine urokinase-type plasminogen activator. High-affinity inhibitory peptide variants were identified as those that conferred to the fusion protease the lowest activity for substrate hydrolysis. The usefulness of the strategy was demonstrated by the selection of peptidic inhibitors of murine urokinase-type plasminogen activator with a low nanomolar affinity. The high affinity could not have been predicted by rational considerations, as the high affinity was associated with a loss of polar interactions and an increased binding entropy.
[Display omitted]
•The back-flip strategy, as demonstrated here with a peptidic protease inhibitor, provides a practical approach to engineering peptidic protein modulators in general and to mapping peptide–protein interaction surfaces.•The usefulness of the back-flip strategy is demonstrated by a rationally unpredictable improvement of a peptidic protease inhibitor following the loss of a peptide–protein polar interaction and an entropy penalty.•The high affinity of the new peptidic inhibitors to their target enzyme appears to be caused by their flexibility, enabling them to adapt to variable enzyme surfaces.</description><subject>Amino Acid Sequence</subject><subject>Animals</subject><subject>Cell Line</subject><subject>conformation</subject><subject>Crystallography, X-Ray</subject><subject>Drug Discovery</subject><subject>Entropy</subject><subject>fusion protein</subject><subject>glycine</subject><subject>Humans</subject><subject>Mice</subject><subject>Molecular Sequence Data</subject><subject>mupain-1</subject><subject>Peptide Library</subject><subject>Peptides, Cyclic - chemistry</subject><subject>Peptides, Cyclic - metabolism</subject><subject>Peptides, Cyclic - pharmacology</subject><subject>phage display</subject><subject>Protein Conformation</subject><subject>Recombinant Fusion Proteins - chemistry</subject><subject>Recombinant Fusion Proteins - metabolism</subject><subject>Serine Endopeptidases - chemistry</subject><subject>Serine Endopeptidases - metabolism</subject><subject>Serine Proteinase Inhibitors - chemistry</subject><subject>Serine Proteinase Inhibitors - metabolism</subject><subject>Serine Proteinase Inhibitors - pharmacology</subject><subject>Urokinase-Type Plasminogen Activator - antagonists & inhibitors</subject><subject>Urokinase-Type Plasminogen Activator - chemistry</subject><subject>Urokinase-Type Plasminogen Activator - metabolism</subject><issn>0022-2836</issn><issn>1089-8638</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp9kcFu3CAURVHVKplO8wHdVCy7sQvYOLa6SqJME2mkRkq6RhieM29qgwueVLPrPyRf2C8p1qRZZoUQhwPvXkI-cpZzxqsv23w7tLlgXOaszhmTb8iCs7rJ6qqo35IFY0Jkoi6qY_I-xi1LRFHWR-RYVKLmp5wvyNMt9GAm9I76jl7h_SY76zp0OO3pDYwTWjT0FgI6oDfBT6Aj0Gu3wRYnHyL9jdMm7U2YDyw9R2fR3dNLNwU_7mkX_EA1PdfmZ7bqcaRrbIMO-_mxgx7-_nl8Ea92Mf0kfiDvOt1HOHlel-TH6vLu4ipbf_92fXG2zkwpiikTtjFclsZKbgS0WrRMCyaFZMxqDsbIohWlLUVjteZNwYFZA_q04EIzU-liST4fvGPwv3YQJzVgNND32oHfRZUikpVsmkIklB9QE3yMATo1BhzSJIozNZehtiqVoeYyFKvVHPWSfHrW79oB7MuN_-kn4OsBgDTkA0JQ0SA4AxZDKkVZj6_o_wFq1Z1X</recordid><startdate>20150925</startdate><enddate>20150925</enddate><creator>Sørensen, Hans Peter</creator><creator>Xu, Peng</creator><creator>Jiang, Longguang</creator><creator>Kromann-Hansen, Tobias</creator><creator>Jensen, Knud J.</creator><creator>Huang, Mingdong</creator><creator>Andreasen, Peter A.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0085-9141</orcidid></search><sort><creationdate>20150925</creationdate><title>Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide–Protease Fusions</title><author>Sørensen, Hans Peter ; Xu, Peng ; Jiang, Longguang ; Kromann-Hansen, Tobias ; Jensen, Knud J. ; Huang, Mingdong ; Andreasen, Peter A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-2d9c154cd51c2eba2b0a2052500da1ecc53b24d429daa1931e0dcea7312a0c6a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Amino Acid Sequence</topic><topic>Animals</topic><topic>Cell Line</topic><topic>conformation</topic><topic>Crystallography, X-Ray</topic><topic>Drug Discovery</topic><topic>Entropy</topic><topic>fusion protein</topic><topic>glycine</topic><topic>Humans</topic><topic>Mice</topic><topic>Molecular Sequence Data</topic><topic>mupain-1</topic><topic>Peptide Library</topic><topic>Peptides, Cyclic - chemistry</topic><topic>Peptides, Cyclic - metabolism</topic><topic>Peptides, Cyclic - pharmacology</topic><topic>phage display</topic><topic>Protein Conformation</topic><topic>Recombinant Fusion Proteins - chemistry</topic><topic>Recombinant Fusion Proteins - metabolism</topic><topic>Serine Endopeptidases - chemistry</topic><topic>Serine Endopeptidases - metabolism</topic><topic>Serine Proteinase Inhibitors - chemistry</topic><topic>Serine Proteinase Inhibitors - metabolism</topic><topic>Serine Proteinase Inhibitors - pharmacology</topic><topic>Urokinase-Type Plasminogen Activator - antagonists & inhibitors</topic><topic>Urokinase-Type Plasminogen Activator - chemistry</topic><topic>Urokinase-Type Plasminogen Activator - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sørensen, Hans Peter</creatorcontrib><creatorcontrib>Xu, Peng</creatorcontrib><creatorcontrib>Jiang, Longguang</creatorcontrib><creatorcontrib>Kromann-Hansen, Tobias</creatorcontrib><creatorcontrib>Jensen, Knud J.</creatorcontrib><creatorcontrib>Huang, Mingdong</creatorcontrib><creatorcontrib>Andreasen, Peter A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of molecular biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sørensen, Hans Peter</au><au>Xu, Peng</au><au>Jiang, Longguang</au><au>Kromann-Hansen, Tobias</au><au>Jensen, Knud J.</au><au>Huang, Mingdong</au><au>Andreasen, Peter A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide–Protease Fusions</atitle><jtitle>Journal of molecular biology</jtitle><addtitle>J Mol Biol</addtitle><date>2015-09-25</date><risdate>2015</risdate><volume>427</volume><issue>19</issue><spage>3110</spage><epage>3122</epage><pages>3110-3122</pages><issn>0022-2836</issn><eissn>1089-8638</eissn><abstract>We have developed a new concept for designing peptidic protein modulators, by recombinantly fusing the peptidic modulator, with randomized residues, directly to the target protein via a linker and screening for internal modulation of the activity of the protein. We tested the feasibility of the concept by fusing a 10-residue-long, disulfide-bond-constrained inhibitory peptide, randomized in selected positions, to the catalytic domain of the serine protease murine urokinase-type plasminogen activator. High-affinity inhibitory peptide variants were identified as those that conferred to the fusion protease the lowest activity for substrate hydrolysis. The usefulness of the strategy was demonstrated by the selection of peptidic inhibitors of murine urokinase-type plasminogen activator with a low nanomolar affinity. The high affinity could not have been predicted by rational considerations, as the high affinity was associated with a loss of polar interactions and an increased binding entropy.
[Display omitted]
•The back-flip strategy, as demonstrated here with a peptidic protease inhibitor, provides a practical approach to engineering peptidic protein modulators in general and to mapping peptide–protein interaction surfaces.•The usefulness of the back-flip strategy is demonstrated by a rationally unpredictable improvement of a peptidic protease inhibitor following the loss of a peptide–protein polar interaction and an entropy penalty.•The high affinity of the new peptidic inhibitors to their target enzyme appears to be caused by their flexibility, enabling them to adapt to variable enzyme surfaces.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>26281711</pmid><doi>10.1016/j.jmb.2015.08.005</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0003-0085-9141</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-2836 |
ispartof | Journal of molecular biology, 2015-09, Vol.427 (19), p.3110-3122 |
issn | 0022-2836 1089-8638 |
language | eng |
recordid | cdi_proquest_miscellaneous_1715659932 |
source | ScienceDirect Freedom Collection |
subjects | Amino Acid Sequence Animals Cell Line conformation Crystallography, X-Ray Drug Discovery Entropy fusion protein glycine Humans Mice Molecular Sequence Data mupain-1 Peptide Library Peptides, Cyclic - chemistry Peptides, Cyclic - metabolism Peptides, Cyclic - pharmacology phage display Protein Conformation Recombinant Fusion Proteins - chemistry Recombinant Fusion Proteins - metabolism Serine Endopeptidases - chemistry Serine Endopeptidases - metabolism Serine Proteinase Inhibitors - chemistry Serine Proteinase Inhibitors - metabolism Serine Proteinase Inhibitors - pharmacology Urokinase-Type Plasminogen Activator - antagonists & inhibitors Urokinase-Type Plasminogen Activator - chemistry Urokinase-Type Plasminogen Activator - metabolism |
title | Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide–Protease Fusions |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T10%3A10%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Selection%20of%20High-Affinity%20Peptidic%20Serine%20Protease%20Inhibitors%20with%20Increased%20Binding%20Entropy%20from%20a%20Back-Flip%20Library%20of%20Peptide%E2%80%93Protease%20Fusions&rft.jtitle=Journal%20of%20molecular%20biology&rft.au=S%C3%B8rensen,%20Hans%20Peter&rft.date=2015-09-25&rft.volume=427&rft.issue=19&rft.spage=3110&rft.epage=3122&rft.pages=3110-3122&rft.issn=0022-2836&rft.eissn=1089-8638&rft_id=info:doi/10.1016/j.jmb.2015.08.005&rft_dat=%3Cproquest_cross%3E1715659932%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c423t-2d9c154cd51c2eba2b0a2052500da1ecc53b24d429daa1931e0dcea7312a0c6a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1715659932&rft_id=info:pmid/26281711&rfr_iscdi=true |